ADCs (Antibody Drug Conjugates) combines the best of two modalities, toxic efficacy, and antibody specificity. The result is an improved therapeutic window with fewer side effects. However, the bioanalytical requirements for PK analysis also require a multifaceted approach. Here we describe various mass spectrometry-based strategies Frontage has successfully applied in the bioanalysis of ADCs for clinical and preclinical studies.

In this infographic, we describe various mass spectrometry-based strategies Frontage has successfully applied in the bioanalysis of ADCs for clinical and preclinical studies. Antibody-drug conjugates (ADCs) combine the best of two modalities: toxin efficacy and antibody specificity. The result is an improved therapeutic window with fewer side effects but the bioanalytical requirements for PK analysis also require a multifaceted approach.

In this eBook, we explore the various ways LC-MS is utilized for the bioanalysis of ADCs and the strategies used for ADCs in biotherapeutics and clinical development.